Gluten Intolerance Treatment Market Analysis

  • Report ID: 5081
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Gluten Intolerance Treatment Market Analysis

Gluten Intolerance Treatment Segmentation

Gluten-Related Disorders {Celiac Disease (CD), Dermatitis Herpetiformis (DH), Gluten Ataxia (GA), Wheat Allergy (WA), Non-Celiac Gluten Sensitivity (NCGS)}

The celiac disease segment in the gluten intolerance treatment market is set to hold the largest revenue share of 40% by 2036. Celiac disease is one of the most common examples of several types of gluten intolerance and people with celiac disease also use gluten intolerance treatment as they have high levels of certain antibodies in their blood, which are substances that fight gluten.

The increasing prevalence of celiac disease which is a serious autoimmune disease where the ingestion of gluten leads to damage in the small intestine is also considered to propel the segment growth. According to a prediction, celiac disease affects 1 in 100 people worldwide, but only around 30% are properly diagnosed. Moreover, as gluten sensitivity and celiac disease cause a lot of the same symptoms, the increase in the disease share is expected to provide numerous growth opportunities to the market players.

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Specialty Pharmacy, Online Pharmacy)

Gluten intolerance treatment market from the retail pharmacy segment is poised to register significant growth rate through 2036, owing to the rise in demand for over-the-counter (OTC) medications. Going forward most gluten-tolerance or allergy drugs need a prescription for an over-the-counter allergy drug which is predicted to be the major growth factor of the segment.

Our in-depth analysis of the market includes the following segments:

            Type

  • Antihistamines
  • Epinephrine

           Gluten-Related Disorders

  • Celiac Disease (CD)
  • Dermatitis Herpetiformis (DH)
  • Gluten Ataxia (GA)
  • Wheat Allergy (WA)
  • Non-Celiac Gluten Sensitivity (NCGS)

           Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy
 
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5081
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gluten intolerance treatment is estimated at USD 832.97 Million.

The gluten intolerance treatment market size was valued at USD 740.35 Million in 2023 and is likely to cross USD 4.02 Billion by the end of 2036, registering more than 13.9% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora are the major factors driving the market growth.

Asia Pacific region is projected to account for 25% revenue share by 2036, due to growing concern about gluten intolerance in the region.

Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample